| MeSH term | MeSH ID | Detail |
|---|---|---|
| Intertrigo | D007402 | 1 associated lipids |
| Impetigo | D007169 | 3 associated lipids |
| Nocturnal Myoclonus Syndrome | D020189 | 1 associated lipids |
| Pterygium | D011625 | 3 associated lipids |
| Amyloid Neuropathies | D017772 | 1 associated lipids |
| Mucinoses | D017520 | 2 associated lipids |
| Carcinoma, Merkel Cell | D015266 | 2 associated lipids |
| Nocturia | D053158 | 1 associated lipids |
| Failed Back Surgery Syndrome | D055111 | 3 associated lipids |
| Malacoplakia | D008287 | 1 associated lipids |
| Myelitis | D009187 | 1 associated lipids |
| Erythroplasia | D004919 | 1 associated lipids |
| Migraine with Aura | D020325 | 1 associated lipids |
| Hutchinson's Melanotic Freckle | D018327 | 2 associated lipids |
| Lacerations | D022125 | 1 associated lipids |
| Trauma, Nervous System | D020196 | 2 associated lipids |
| Central Nervous System Viral Diseases | D020805 | 1 associated lipids |
| Neuroaspergillosis | D020953 | 2 associated lipids |
| Hepatopulmonary Syndrome | D020065 | 1 associated lipids |
| Arm Injuries | D001134 | 1 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- J. Pharmacol. Exp. Ther. (1)
- Am. J. Physiol. Renal Physiol. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Cacciarelli TV et al. | An analysis of pretransplantation variables associated with long-term allograft outcome in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. | 1999 | Transplantation | pmid:10507484 |
| Burroughs TE et al. | Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. | 2007 | Transplantation | pmid:17452891 |
| Vincenti F | A decade of progress in kidney transplantation. | 2004 | Transplantation | pmid:15201687 |
| Burke GW et al. | Advances in pancreas transplantation. | 2004 | Transplantation | pmid:15201688 |
| Pfitzmann R et al. | Mycophenolatemofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients. | 2003 | Transplantation | pmid:12865798 |
| Moss MC et al. | Lithium use for bipolar disorder post renal transplant: is mood stabilization without toxicity possible? | 2014 | Transplantation | pmid:24492429 |
| Fridell JA et al. | Steroid withdrawal for pancreas after kidney transplantation in recipients on maintenance prednisone immunosuppression. | 2006 | Transplantation | pmid:16906038 |
| Narayanan M et al. | Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression. | 2013 | Transplantation | pmid:23423268 |
| Moffatt SD et al. | Potential for improved therapeutic index of FK506 in liposomal formulation demonstrated in a mouse cardiac allograft model. | 1999 | Transplantation | pmid:10342309 |
| Yoshihara S et al. | Successful treatment of life-threatening human herpesvirus-6 encephalitis with donor lymphocyte infusion in a patient who had undergone human leukocyte antigen-haploidentical nonmyeloablative stem cell transplantation. | 2004 | Transplantation | pmid:15077022 |
| Bierer BE et al. | Mechanisms of immunosuppression by FK506. Preservation of T cell transmembrane signal transduction. | 1990 | Transplantation | pmid:1694317 |
| Yin DP et al. | Lewis rat pancreas, but not cardiac xenografts, are resistant to anti-gal antibody mediated hyperacute rejection. | 2001 | Transplantation | pmid:11391223 |
| Krentz AJ | Posttransplantation Diabetes Mellitus in FK-506-Treated Renal Transplant Recipients: Analysis of Incidence and Risk Factors. Transplantation 2001; 72: 1655. | 2001 | Transplantation | pmid:11726815 |
| Bruce DS et al. | Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients. | 2001 | Transplantation | pmid:11726823 |
| Egeland EJ et al. | High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation. | 2017 | Transplantation | pmid:28452920 |
| Hsiau M et al. | Monitoring nonadherence and acute rejection with variation in blood immunosuppressant levels in pediatric renal transplantation. | 2011 | Transplantation | pmid:21857278 |
| Yates CJ et al. | Screening for new-onset diabetes after kidney transplantation: limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin. | 2013 | Transplantation | pmid:23902993 |
| Kaplan B et al. | Frequency of hyperkalemia in recipients of simultaneous pancreas and kidney transplants with bladder drainage. | 1996 | Transplantation | pmid:8900321 |
| Bronster DJ et al. | Tacrolimus-associated mutism after orthotopic liver transplantation. | 2000 | Transplantation | pmid:11014653 |
| Lufft V et al. | Incidence of Pneumocystis carinii pneumonia after renal transplantation. Impact of immunosuppression. | 1996 | Transplantation | pmid:8779695 |
| Yu S et al. | Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. | 2006 | Transplantation | pmid:16421475 |
| Muraki T et al. | Effects of cyclosporine and FK506 on in vitro high shear-induced platelet reactivity in rat and human non-anticoagulated blood. | 1998 | Transplantation | pmid:9583878 |
| Kadry Z et al. | Kaposi's sarcoma in liver transplant recipients on FK506. | 1998 | Transplantation | pmid:9583882 |
| Ho ET et al. | Once-daily extended-release versus twice-daily standard-release tacrolimus in kidney transplant recipients: a systematic review. | 2013 | Transplantation | pmid:23542469 |
| Shapiro R et al. | Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. | 2008 | Transplantation | pmid:18431232 |
| Porrini E et al. | Prediabetes in patients receiving tacrolimus in the first year after kidney transplantation: a prospective and multicenter study. | 2008 | Transplantation | pmid:18431233 |
| Veroux M et al. | Impact of conversion to a once daily tacrolimus-based regimen in kidney transplant recipients with gastrointestinal complications. | 2012 | Transplantation | pmid:22298033 |
| Inoue T et al. | Lesser reduction in bone mineral density by the immunosuppressant, FK506, compared with cyclosporine in rats. | 2000 | Transplantation | pmid:11003356 |
| Yang H et al. | Liposomal encapsulation significantly enchances the immunosuppressive effect of tacrolimus in a discordant islet xenotransplant model. | 2002 | Transplantation | pmid:11907415 |
| St A Nunes FA and Lucey MR | Searching for a balance when applying immunosuppression after liver transplantation. | 2001 | Transplantation | pmid:11258425 |
| Podesser BK et al. | Comparison of low and high initial tacrolimus dosing in primary heart transplant recipients: a prospective European multicenter study. | 2005 | Transplantation | pmid:15714171 |
| Steinmüller TM et al. | The effect of FK506 versus cyclosporine on glucose and lipid metabolism--a randomized trial. | 1994 | Transplantation | pmid:7524203 |
| Sonoda T et al. | Outcome of 3 years of immunosuppression with tacrolimus in more than 1,000 renal transplant recipients in japan. | 2003 | Transplantation | pmid:12548123 |
| Roberti I et al. | Evidence that the systematic analysis of bile cytology permits monitoring of hepatic allograft rejection. | 1992 | Transplantation | pmid:1384182 |
| Guthery SL et al. | Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. | 2003 | Transplantation | pmid:12698085 |
| Jain A et al. | The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis. | 2003 | Transplantation | pmid:12698091 |
| Peng Y et al. | Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. | 2013 | Transplantation | pmid:23263506 |
| Murase N et al. | Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. | 1993 | Transplantation | pmid:7678353 |
| Chan L et al. | Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. | 2010 | Transplantation | pmid:20517177 |
| Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Drug levels in PHAs who receive liver transplants. | 2003 Apr-May | TreatmentUpdate | pmid:17216847 | |
| Kunz J and Hall MN | Cyclosporin A, FK506 and rapamycin: more than just immunosuppression. | 1993 | Trends Biochem. Sci. | pmid:7694398 |
| Cardenas ME et al. | Signal-transduction cascades as targets for therapeutic intervention by natural products. | 1998 | Trends Biotechnol. | pmid:9807840 |
| Snyder SH et al. | Neural actions of immunophilin ligands. | 1998 | Trends Pharmacol. Sci. | pmid:9509898 |
| Liu J | FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. | 1993 | Trends Pharmacol. Sci. | pmid:7692652 |
| Chang JY et al. | FK506 and rapamycin: novel pharmacological probes of the immune response. | 1991 | Trends Pharmacol. Sci. | pmid:1710854 |
| Sommerer C et al. | Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial. | 2016 | Trials | pmid:26888217 |
| Nashan B et al. | Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial. | 2015 | Trials | pmid:25873064 |
| Bajetta E et al. | Merkel cell carcinoma after liver transplantation: a case report. | 2007 May-Jun | Tumori | pmid:17679476 |
| Vennarecci G et al. | [Acute liver toxicity of antiretroviral therapy (HAART) after liver transplantation in a patient with HIV-HCV coinfection and associated hepatocarcinoma (HCC)]. | 2003 Jul-Aug | Tumori | pmid:12903579 |
| Tümgör G et al. | A case of uneventful ABO-incompatible liver transplantation from a deceased donor managed with routine immunosuppressive treatment. | 2014 | Turk J Gastroenterol | pmid:25599790 |